FDA 批准帕博利珠单抗用于卡介苗无应答性非肌层浸润性膀胱癌。
FDA Approves Pembrolizumab for BCG-Unresponsive NMIBC.
出版信息
Oncology (Williston Park). 2020 Feb 20;34(2):44.
PMID:32645193
Abstract
The FDA approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.
摘要
美国食品和药物管理局（FDA）批准帕博利珠单抗（Keytruda）用于治疗卡介苗（BCG）无应答、高危、非肌肉浸润性膀胱癌（NMIBC）伴原位癌（CIS）伴或不伴乳头状肿瘤的患者，这些患者不适合或选择不接受膀胱切除术。
Zotero 插件